48878 Federal Register / Vol. 62, No. 180 / Wednesday, September 17, 1997 / Notices

Subject, city, state Effective date

PETROSKY, MICHAEL J., COVINGTON, LA ..................................................................................................................................... 08/26/97

PUIG, XIOMARA, MIAMI, FL ............................................................................................................................................................... 09/03/97

RABAH, WAJIH I., AGUADILLA, PR ................................................................................................................................................... 09/02/97

RADI, ANTHONY W., HICKSVILLE, NY ............................................................................................................................................. 09/02/97

ROJAS, EDUARDO ANTONIO, ALTAMONTE SPRINGS, FL ........................................................................................................... 09/03/97

ROTHERY, BEVERLY A., MARIETTA, OH ........................................................................................................................................ 08/27/97

SALOMON, ALIX P., CHICAGO, IL .................................................................................................................................................... 08/27/97

SANCIO, ELAINE D. WITTERSCHEIN, JERSEY CITY, NJ ............................................................................................................... 09/02/97

SANSONE, PETER J. (SAMSONE), BROOKLYN, NY ...................................................................................................................... 09/02/97

SMITH, RICKEY E., JAMAICA PLAIN, MA ......................................................................................................................................... 08/27/97

SMITH, BRENT R., SPRING ARBOR, MI ........................................................................................................................................... 09/02/97

SNYDER, CHARLOTTE J., STOCKTON, KS ..................................................................................................................................... 09/03/97

STONE, BRETT E., POTEAU, OK ...................................................................................................................................................... 08/26/97

THOMPSON, BYRON J., CHICAGO, IL ............................................................................................................................................. 09/02/97

TWOMLEY, JAMES D., HOLLAND, IN ............................................................................................................................................... 09/02/97

WALL, HOMER G., LINCOLN, NE ...................................................................................................................................................... 09/03/97

WASHINGTON, GENEVA (WALKER), DAYTON, OH ........................................................................................................................ 09/02/97

WELDEN, SHIRLEY J., TULSA, OK ................................................................................................................................................... 08/26/97

SECTION 1128Aa

RAINBOW HOME MEDICAL EQPT CO., MIAMI, FL ......................................................................................................................... 06/20/97

RODRIGUEZ, LEONOR, MIAMI BEACH, FL ...................................................................................................................................... 06/20/97

143 MEDICAL EQUIPMENT CO., MIAMI, FL ..................................................................................................................................... 06/20/97

Dated: September 3, 1997.

William M. Libercci,

Director, Health Care Administrative

Sanctions, Office of Enforcement and

Compliance.

[FR Doc. 97–24656 Filed 9–16–97; 8:45 am]

BILLING CODE 4150–04–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Consensus Development Conference

on Effective Medical Treatment of

Heroin Addiction

Notice is hereby given of the NIH

Consensus Development Conference on

‘‘Effective Medical Treatment of Heroin

Addiction,’’ which will be held

November 17–19, 1997, in the Natcher

Conference Center of the National

Institutes of Health, 9000 Rockville

Pike, Bethesda, Maryland 20892. The

conference begins at 8:30 a.m. on

November 17, at 8:30 a.m. on November

18, and at 9 a.m. on November 19.

In the United States alone,

approximately one-half million people

are addicted to heroin. Estimates of

heroin incidence (122,000 new users) in

recent years suggest an increased

incidence and an emerging pattern of

drug use among the young. For many

years, heroin addiction has been

associated with increased criminal

activity and human suffering. In the past

10 years, there has been a dramatic

increase in the prevalence of human

immunodeficiency virus (HIV), hepatitis

C virus (HCV), and tuberculosis among

intravenous heroin users. From 1991 to

1995 in major metropolitan areas, the

annual number of heroin-related

emergency room visits has increased

from 36,000 to 76,000, and the annual

number of heroin-related deaths has

increased from 2,300 to 4,000. The

associated morbidity and mortality

further underscore the human,

economic, and societal cost of heroin

addiction.

Over the last 20 years, a significant

body of evidence has accumulated on

the neurobiology of heroin addiction

and on the safety and efficacy of

narcotic (methadone) maintenance

treatment.

Although there have been other

medications (e.g., levo-alpha

acetylmethadol [LAAM]) subsequently

determined safe and effective in

narcotic maintenance treatment, the

focus of this consensus development

conference will be on methadone,

because methadone has been the

medication used in most narcotic

treatment research. Evaluation studies

have consistently shown methadone

treatment to be effective in reducing

drug use and crime and in enhancing

social productivity. More recent studies

demonstrate that methadone treatment

is an effective method for preventing the

spread of HIV, HCV, and tuberculosis

among intravenous drug users.

Most heroin users are not receiving

treatment. Most recent data indicate that

there are approximately 112,000

patients in narcotic maintenance

treatment. Barriers exist to both access

to narcotic maintenance treatment and

effective treatment, despite the science

on the neurobiology of heroin addiction

and the evidence demonstrating the

effectiveness of treatment in reducing

drug use and crime and preventing the

spread of HIV and HCV. An important

reason for some of these barriers is that

narcotic maintenance treatment remains

controversial. The science has not yet

overcome the stigma of addiction and

public perception about narcotic

maintenance treatment.

Many members of the medical

community and the public conceive of

opiate addiction as a self-inflicted

disease of the will, methadone treatment

as mere narcotic substitution and

relapses likely to follow treatment, drugfree treatment as the only valid

rehabilitative method, and total

abstinence from all drugs, including

methadone, as the only valid treatment

goal. Other obstacles include Federal

and state government regulations

limiting treatment providers and patient

access and concerns about methadone

diversion by patients and its

consequences.

To address the most important and

controversial issues surrounding

narcotic maintenance treatment, the

NIH has organized this 21⁄2 day

conference to present the available data

on opiate agonist treatment for heroin

addiction. The conference will bring

together national and international

experts in the fields of basic and clinical

neuroscience, epidemiology, and

natural history, prevention and

treatment of heroin addiction, as well as

representatives from the public.

After 11⁄2 days of presentations and

audience discussion, an independent,

non-Federal consensus panel chaired by

Dr. Lewis Judd, chair of the Department
Federal Register / Vol. 62, No. 180 / Wednesday, September 17, 1997 / Notices 48879

of Psychiatry at the University of

California at San Diego School of

Medicine, will weigh the scientific

evidence and write a draft statement

that will be presented to the audience

on the third day. The consensus

statement will address the following key

questions:

* What is the scientific evidence to

support a conceptualization of opiate

addiction as a medical disorder

including natural history, genetics and

risk factors, pathophysiology, and how

is diagnosis established?

* What are the consequences of

untreated opiate addiction to

individuals, families and society?

* What is the efficacy of current

treatment modalities in the management

of opiate addiction including

detoxification alone, nonpharmacological/psychosocial

treatment, treatment with opiate

antagonists, and treatment with opiate

agonists (short-term and long-term)?

* What is the (scientific evidence for

the) most effective use of opiate agonists

in the treatment of opiate addiction?

* What are the important barriers to

effective use of opiate agonists in the

treatment of opiate addiction in the

U.S., including perceptions and the

adverse consequences of opiate agonist

use, legal, regulatory, financial and

programmatic barriers?

* What are the future research areas

and recommendations for improving

opiate agonist treatment and improving

access?

The primary sponsors of this meeting

are the National Institute on Drug Abuse

and the NIH Office of Medical

Applications Research. The conference

is co-sponsored by the NIH Office of

Research on Women’s Health.

Advance information on the

conference program and conference

registration materials may be obtained

from Prospect Associates, 1801

Rockville Pike, Suite 500, Rockville,

Maryland 20852, (301) 468–MEET, by

e-mail at

NIHconsensus@ProspectAssoc.com, or

by visiting http://consensus.nih.gov on

the World Wide Web.

The consensus statement will be

submitted for publication in

professional journals and other

publications. In addition, the statement

will be available beginning November

19, 1997, from the NIH Consensus

Program Information Center, P.O. Box

2577, Kensington, Maryland 20891,

phone 1–888–NIH–CONSENSUS (1–

888–644–2667) and from the NIH

Consensus Development Program site

on the World Wide Web at http://

consensus.nih.gov.

Dated: September 4, 1997.

Ruth L. Kirschstein,

Deputy Director, NIH.

[FR Doc. 97–24628 Filed 9–16–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Meeting of the National Cancer

Advisory Board and its Subcommittees

Pursuant to Pub. L. 92–463, as

amended, notice is hereby given of the

meeting of the National Cancer

Advisory Board (Board), National

Cancer Institute (NCI), and its

Subcommittees on September 23–25,

1997. The meetings of the Board and its

Subcommittees will be open to the

public as indicated below. Attendance

by the public will be limited to space

available.

A portion of the Board meeting will

be closed to the public in accordance

with the provisions set forth in secs.

552b(c)(4), 552b(c)(6), and 552(c)(9)(B),

Title 5 U.S.C. and sec. 10(d) of Pub. L.

92–463, for the review, discussion and

evaluation of individual grant

applications and for discussion of issues

pertaining to programmatic areas and/or

NCI personnel. These applications and

discussions could reveal confidential

trade secrets or commercial property

such as patentable material, and

personal information concerning the

individuals associated with the

applications or programs, the disclosure

of which would constitute a clearly

unwarranted invasion of personal

privacy, and premature disclosure of

recommendations which would be

likely to significantly frustrate the

subsequent implementation of those

recommendations.

The Committee Management Office,

National Cancer Institute, National

Institutes of Health, Executive Plaza

North, Room 609, 6130 Executive

Boulevard, MSC 7410, Bethesda,

Maryland 20892–7410, (301) 496–5708

will provide summaries of the meetings

and rosters of the Board members, upon

request.

Individuals who plan to attend and

need special assistance, such as sign

language interpretation or other

reasonable accommodations, should

contact Mrs. Linda Quick-Cameron,

Committee Management Officer, at (301)

496–5708 in advance of the meeting.

Name of Committee: Subcommittee on

Activities and Agenda.

Contact Person: Dr. Marvin R. Kalt,

Executive Secretary, National Cancer

Institute, NIH, Executive Plaza North, Room

600, 6130 Executive Blvd., MSC 7405,

Bethesda, MD 20892–7405, (301) 496–5147.

Date of Meeting: September 23, 1997.

Place of Meeting: Bethesda Marriott Hotel

(Pooks Hill), 5151 Pooks Hill Road, Bethesda,

MD 20814.

Closed: 7:00 p.m. to 9:00 p.m.

Agenda: To Conduct Preliminary

Discussion of Future Programmatic and

Personnel Activities and Policies.

Name of Committee: Subcommittee on

Planning and Budget.

Contact Person: Ms. Cherie Nichols,

Executive Secretary, National Cancer

Institute, NIH, 7550 Wisconsin Avenue,

Room 312, MSC 9010, Bethesda, MD 20892–

9010, (301) 496–5515.

Date of Meeting: September 24, 1997.

Place of Meeting: Building 31, Conference

Room 8/C Wing, National Institutes of

Health, 9000 Rockville Pike, Bethesda, MD

20892.

Open: 12:30 p.m. to 1:30 p.m.

Agenda: To Discuss the NCI Budget and

Various Planning Issues.

Name of Committee: Subcommittee on

Special Actions for Grants.

Contact Person: Dr. Marvin R. Kalt,

Executive Secretary, National Cancer

Institute, NIH, Executive Plaza North, Room

600, 6130 Executive Blvd., MSC 7405,

Bethesda, MD. 20892–7405, (301) 496–5147.

Date of Meeting: September 24, 1997.

Place of Meeting: Building 31, Conference

Room 10/C Wing, National Institutes of

Health, 9000 Rockville Pike, Bethesda, MD.

20892.

Closed: 4:05 p.m. to Adjournment.

Agenda: To Review and Discuss Grant

Applications and Extramural/Intramural,

Programmatic and Personnel Policies.

Name of Committee: Subcommittee on

Clinical Investigations.

Contact Person: Dr. Robert Wittes,

Executive Secretary, National Cancer

Institute, NIH, Building 31, Room 3A44, MSC

2440, 9000 Rockville Pike, Bethesda, MD

20892–2440, (301) 496–4291.

Date of Meeting: September 25, 1997.

Place of Meeting: Building 31, Conference

Room 8/C Wing, National Institutes of

Health, 9000 Rockville Pike, Bethesda, MD.

20892.

Open: 12:30 p.m. to 1:45 p.m.

Agenda: To Discuss the Design of

Prospective Studies of the Impact of Managed

Care on Cancer Clinical Investigations,

Education and Training.

Name of Committee: National Cancer

Advisory Board.

Contact Person: Dr. Marvin R. Kalt,

Executive Secretary, National Cancer

Institute, NIH, Executive Plaza North, Room

600, 6130 Executive Blvd., MSC 7405,

Bethesda, MD. 20892–7405, (301) 496–5147.

Dates of Meeting: September 24–25, 1997.

Place of Meeting: Building 31, Conference

Room 10/C Wing, National Institutes of

Health, 9000 Rockville Pike, Bethesda, MD.

20892.

Open: September 24—8:30 a.m. to 4:00

p.m.; September 25—8:30 a.m. to 4:00 p.m.